Q2 2025 Earnings Call Transcript July 16, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Johnson & Johnson stands second among the most ...

Investing.com -- Johnson & Johnson (NYSE: JNJ) announced Wednesday that the European Commission has approved its Darzalex subcutaneous formulation as a monotherapy for adults with high-risk ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Premier Strategy” ...

The company’s stock JNJ is climbing in morning trading, boosted by better-than-expected second-quarter results and raised ...

Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and ...

Johnson & Johnson revised its fiscal year 2025 guidance. The company expects adjusted earnings of $10.80-$10.90, up from ...

Johnson & Johnson (NYSE:JNJ) has long been considered one of the most dependable dividend stocks, having increased its ...

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...

Johnson & Johnson delivered a "beat and raise" quarter. Results were bolstered by the new acquisition of Intra-Cellular, ...